A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects

Roy B. Jones, Keith E. Stockerl-Goldstein, Jared Klein, James Murphy, Karl G. Blume, Roger Dansey, Charles Martinez, Steven Matthes, Yago Nieto

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

We conducted a randomized, double blind, placebo-controlled multi-institutional trial to assess the ability of amifostine to protect patients against acute lung injury associated with cyclophosphamide/cisplatin/carmustine (BCNU) (STAMP I), a BCNU-containing high dose chemotherapy regimen used with hematopoietic cell transplantation. Amifostine was administered in a dose of 740 mg/m2 for 2 doses preceding administration of BCNU, the presumed pulmonary-toxic component of the regimen. The trial was stopped after 79 patients were randomized and a planned interim analysis demonstrated that it was unlikely that pulmonary cytoprotection would be detected with further accrual. We conclude that amifostine, used in the dose and schedule we tested, does not reduce the incidence of acute lung injury produced by STAMP I. Further, we suggest that amifostine use with BCNU in other contexts and with clinically achievable doses is unlikely to protect the lung from BCNU-associated acute injury.

Original languageEnglish
Pages (from-to)276-282
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume10
Issue number4
DOIs
StatePublished - Apr 1 2004
Externally publishedYes

Keywords

  • Acute lung injury
  • Amifostine
  • BCNU
  • Hematopoietic cell transplantation

Fingerprint Dive into the research topics of 'A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects'. Together they form a unique fingerprint.

  • Cite this